comms@paragonbiosci.com

58 items

June 22, 2021

Emalex Biosciences Announces Completion of Patient Enrollment in Phase 2b Clinical Trial Evaluating Ecopipam (EBS-101) for Pediatric Patients with Tourette Syndrome
Paragon Biosciences’ Portfolio Company Focuses on Areas [...]
June 3, 2021

Sai Chavala, M.D., Receives ARVO Foundation Ludwig Von Sallmann Clinician-Scientist Award
Dr. Chavala is co-founder of CiRC Biosciences [...]
March 23, 2021

Emalex Biosciences Raises $35 Million in Series C Preferred Stock to Advance Tourette Syndrome and Stuttering Clinical Trials
Funding led by Paragon Biosciences, joined by [...]
March 10, 2021

CiRC Biosciences Announces Orphan Drug Designation for Treatment of Retinitis Pigmentosa (RP)
Cell Therapy Platform Seeks to Restore Vision [...]
February 23, 2021

Paragon Biosciences Appoints Jordan Dubow as Chief Medical Officer
Chicago, February 23, 2021—With continued growth [...]
February 2, 2021

Paragon Biosciences Launches CiRC Biosciences to Expand Cell and Gene Therapy Platform
Its vision restoration technology featured in Nature [...]
December 15, 2020

First Patient Dosed in Emalex Biosciences Phase 2 Clinical Trial for Stuttering
Chicago – December 15, 2020 – Emalex Biosciences, [...]
September 9, 2020

Jon DeVries Named Qlarity Imaging Chief Executive Officer
Chicago, September 9, 2020 – Life science innovator [...]

Previous 345 Next